

**FOR IMMEDIATE RELEASE**



**Contact:**  
Bob Arnold  
Hypertension Diagnostics  
651-687-9999  
barnold@cvchd.com

## **CVC-HD, LLC Acquires Hypertension Diagnostics, Inc.** **New ownership group to restructure and refocus sales and operations**

**St. Paul, MN – August, 2011.** – CVC-HD, LLC, a new holding company for CardioVascular Centers and Hypertension Diagnostics, has closed its acquisition of the assets of Hypertension Diagnostics, Inc. (OTC: HDII.OB).

CVC-HD, LLC will restructure Hypertension Diagnostics (HD) to restore profitability and refocus sales to increase revenues.

“This is a new day for Hypertension Diagnostics”, said Maury Taylor, CEO of CVC-HD, LLC. “We will leverage HD’s technology into new markets and aggressively expand current markets”.

The new HD will emphasize its technological superiority in the early identification of cardiovascular disease, re-emphasize the company’s strong clinical support of its founder, Dr. Jay Cohn, and promote the integration of its technology in the prevention and management of cardiovascular disease.

### **About CVC-HD, LLC**

CVC-HD, LLC ([www.cvchd.com](http://www.cvchd.com)) is a holding company for CardioVascular Centers and Hypertension Diagnostics. We specialize in heart disease detection and evaluation. CardioVascular Centers provides diagnostic screening services for the earliest detection of heart disease known today. Our aim is to prevent and combat the epidemic of heart disease in the world today, minimizing and eliminating heart attacks, strokes, and other cardiovascular complications.

### **About Hypertension Diagnostics**

Hypertension Diagnostics ([www.hypertensiondiagnostics.com](http://www.hypertensiondiagnostics.com)) manufactures and markets medical devices for early detection and management of cardiovascular disease in the U.S. and in 40 countries. Its main product, the CVProfilor® DO-2020 CardioVascular Profiling System, has been approved by the Food and Drug Administration (FDA), and is used by over 600 physicians worldwide. HD’s CardioVascular Profiling Systems non-invasively measure both large and small artery elasticity. Small artery elasticity has been shown to be highly predictive of cardiovascular disease. Several large pharmaceutical manufacturers have used HD’s CardioVascular Profiling Systems in their multi-site clinical research trials. There are over 300 published, peer-reviewed scientific articles and presentations on HD’s methodology, which provides evidence on the validity, accuracy and reproducibility of HD’s CardioVascular Profiling technology. The technology has been granted with 23 patents and was developed at the University of Minnesota by a team led by world-renown cardiologist, Dr. Jay N. Cohn.

CVC-HD LLC, Inc. All rights reserved.

Website: [www.cvchd.com](http://www.cvchd.com)

###